Cover Image
市場調查報告書

Leber遺傳性視神經病變 (LHON) (Leber視神經萎縮 ) :開發中產品分析

Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 325610
出版日期 內容資訊 英文 60 Pages
訂單完成後即時交付
價格
Back to Top
Leber遺傳性視神經病變 (LHON) (Leber視神經萎縮 ) :開發中產品分析 Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H2 2016
出版日期: 2016年09月21日 內容資訊: 英文 60 Pages
簡介

Leber遺傳性視神經病變 (LHON) ,是先天性的視覺障礙之一。通常在10∼20多歲發病,但也有幼兒期和中年期以後發病的稀少案例。男性比起女性發病率高。症狀包含了眼睛疼痛和不舒服、發麻、刺痛、視野糊不清等。原因為年齡和抽煙、酒精、抗癌劑、化學藥品相關壓力、部分抗生素和氰基等。

本報告提供Leber遺傳性視神經病變 (LHON) (Leber視神經萎縮 ) 治療藥的開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等相關的系統性資訊。

目錄

簡介

Leber遺傳性視神經病變 (LHON) (Leber視神經萎縮 )的概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

開發中產品的概要

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

開發中的產品:各企業

研究中的產品:各大學/研究機關

開發治療藥的企業

  • Alkeus Pharmaceuticals, Inc.
  • Biovista Inc.
  • GenSight Biologics S.A.
  • Ixchel Pharma, LLC
  • Khondrion BV
  • Spark Therapeutics, Inc.
  • Stealth BioTherapeutics Inc.

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

暫停的計劃

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8467IDB

Summary

Global Markets Direct's, 'Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H2 2016', provides an overview of the Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy)
  • The report reviews pipeline therapeutics for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) therapeutics and enlists all their major and minor projects
  • The report assesses Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) Overview
  • Therapeutics Development
    • Pipeline Products for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Overview
    • Pipeline Products for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Comparative Analysis
  • Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Therapeutics under Development by Companies
  • Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Therapeutics under Investigation by Universities/Institutes
  • Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Products under Development by Companies
  • Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Products under Investigation by Universities/Institutes
  • Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Companies Involved in Therapeutics Development
    • Alkeus Pharmaceuticals, Inc.
    • Biovista Inc.
    • GenSight Biologics S.A.
    • Ixchel Pharma, LLC
    • Khondrion BV
    • Spark Therapeutics, Inc.
    • Stealth BioTherapeutics Inc.
  • Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • BVA-202 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BVA-203 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug for Lebers Hereditary Optic Neuropathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • elamipretide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate ND4 for Leber's Hereditary Optic Neuropathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GS-010 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GS-011 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IXC-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IXC-203 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KH-176 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SPK-LHON - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Dormant Projects
  • Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Product Development Milestones
    • Featured News & Press Releases
      • Sep 08, 2016: GenSight Biologics Receives Approval to Include Teenage Patients in RESCUE and REVERSE Phase III Trials with GS010 in Leber's Hereditary Optic Neuropathy
      • Jun 08, 2016: GenSight Biologics Announces Additional Promising Results of Its Phase I/II Study with GS010 for the Treatment of Leber's Hereditary Optic Neuropathy (LHON)
      • Jun 01, 2016: Stealth BioTherapeutics Initiates Phase 2 Study of Elamipretide in Leber's Hereditary Optic Neuropathy
      • Feb 29, 2016: GenSight Biologics Enrolls First Patient in Pivotal Phase III Program of GS010 in Leber's Hereditary Optic Neuropathy
      • Sep 10, 2015: GenSight Biologics Receives IND Acceptance from FDA to Enter Phase III with GS010
      • Dec 15, 2014: New CMO joins Khondrion
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy), H2 2016
  • Number of Products under Development for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline by Alkeus Pharmaceuticals, Inc., H2 2016
  • Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline by Biovista Inc., H2 2016
  • Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline by GenSight Biologics S.A., H2 2016
  • Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline by Ixchel Pharma, LLC, H2 2016
  • Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline by Khondrion BV, H2 2016
  • Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline by Spark Therapeutics, Inc., H2 2016
  • Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline by Stealth BioTherapeutics Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy), H2 2016
  • Number of Products under Development for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top